Ollin Biosciences has followed its $100 million Series A last year with a massive $330 million second round that will fuel ...

For GSK, ASCO 2026 was about long-term follow-up data, with new data from ongoing trials of Jemperli and Blenrep. Eric ...

Mike Westby, RQ Bio's chief executive. RQ Bio has raised £85.5 million ($115 million) first-round financing, led by Frazier Life Sciences, to support trials of a one-shot antibody designed to protect ...

HHS acknowledged in a statement on Operation Trailblazer that "a growing share of early-stage clinical research has moved ...

In a landmark decision for people with early type 1 diabetes (T1D) in the UK, Sanofi's first-of-its-kind therapy Tzield, ...

CARSgen Therapeutics has claimed approval in China, its home market, for satricabtagene autoleucel (satri-cel), said to be ...

With the third trial in the programme, Boehringer has set its sights on positioning Hernexeos as adjuvant monotherapy – ...

One of the antibody-drug conjugates at the heart of Pfizer's $43 billion acquisition of Seagen three years ago has failed a keenly anticipated phase 3 trial in lung cancer. The results of the ...

Details are starting to emerge of last week's cyberattack on Novo Nordisk, which now appears to have been a $25 million ...

Men with a particular form of prostate cancer now have a targeted treatment for the first time, thanks to FDA approval of a ...

MSD's tulisokibart has become the first anti-TL1A antibody to help patients with a type of inflammatory bowel disease (IBD) achieve clinical remission in a phase 3 trial. The drug – which MSD acquired ...

Genpact and analyst firm HFS Research have published a new global study, ‘The $18 Trillion Opportunity: How Four Enterprise ...